

Supplementary Table 2. Comparison of baseline characteristics according to the treatment modality

Variable	RFA (n=649)	Resection (n=789)*	P-value
Age (years)			<0.001
<60	384 (59.2)	551 (69.8)	
≥60	265 (40.8)	238 (30.2)	
Male	507 (78.1)	628 (79.6)	0.516
Diabetes	165 (25.4)	115 (14.6)	<0.001
Etiology			<0.001
HBV	485 (74.7)	654 (82.9)	
Others	164 (25.3)	135 (17.1)	
Liver cirrhosis	415 (63.9)	271 (34.3)	<0.001
Child-Pugh score			0.073
5	492 (75.8)	630 (79.8)	
6	157 (24.2)	159 (20.2)	
ALBI grade			<0.001
1	337 (51.9)	493 (62.5)	
2	312 (48.1)	296 (37.5)	
FIB-4 score			<0.001
<1.45	57 (8.8)	188 (23.8)	
≥1.45 and <3.25	230 (35.4)	392 (49.7)	
≥3.25	362 (55.8)	209 (26.5)	
Fibrosis degree			N/A
No or mild fibrosis	N/A	108 (13.7)	
Advanced fibrosis	N/A	321 (40.7)	
Cirrhosis	N/A	360 (45.6)	
AFP (ng/mL)			0.482
<10	265 (40.8)	307 (38.9)	
≥10	384 (59.2)	482 (61.1)	
Tumor number			<0.001
Single	565 (87.1)	757 (95.9)	
Two	74 (11.4)	28 (3.5)	
Three	10 (1.5)	4 (0.5)	
Maximal tumor size (cm)			<0.001
≤2	431 (66.4)	194 (24.6)	
>2 and ≤5	218 (33.6)	467 (59.2)	
>5	0 (0.0)	128 (16.2)	
BCLC stage			<0.001
0	303 (46.7)	139 (17.6)	
A	346 (53.3)	650 (82.4)	

RFA, radiofrequency ablation; HBV, hepatitis B virus; ALBI, albumin-bilirubin; FIB-4 score, fibrosis-4 score; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.

*Thirteen patients who received both RFA and resection were excluded from this analysis.